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Abstract
Elevated lipoprotein(a) [Lp(a)] has been reported to be associated with prothrombotic clot phenotype. We hypothesized that 
increased Lp(a) contributes to cerebral venous sinus thrombosis (CVST) and its recurrence in relation to clot features. In 
80 consecutive patients (aged 39.36 ± 10.18 years, 61 women) following the first CVST after anticoagulation withdrawal, 
we assessed Lp(a) levels and plasma clot properties. Recurrence of CVST was recorded during follow-up (median 53, 
interquartile range 40–59 months). Lp(a) levels were inversely associated with clot permeability  (Ks, r = − 0.58, P < 0.001) 
and the rate of D-dimer release from clots in the presence of tissue plasminogen activator (r = − 0.27, P = 0.017) along with 
increased maximum absorbance of fibrin gels (r = 0.42, P < 0.001) and maximum D-dimer levels achieved during lysis 
(D–Dmax, r = 0.29, P = 0.01). Recurrence of CVST was observed in 12 patients (15%) after median follow-up of 26 months. 
Lp(a) concentrations were higher in patients with recurrence of CVST compared to the remainder (14.15 [8.85–25.25] vs. 
28.3 [18.9–35.6] mg/dL; P = 0.001). The risk of recurrent CVST was fourfold higher among 17 (21.25%) patients with 
Lp(a) > 30 mg/dL compared to the remainder (adjusted hazard ratio, 3.9; 95% confidence interval [CI] 1.23–12.4). Recur-
rence of CVST was associated with 14% lower  Ks (P = 0.001) and 10% higher D–Dmax (P = 0.008), with no differences in 
other clot features. Multiple logistic regression model showed that CVST recurrence was independently associated with 
Lp(a) (odds ratio 1.09, 95% CI 1.02–1.16). Increased Lp(a) characterizes subjects at elevated risk of recurrent CVST after 
anticoagulation withdrawal, which could be partly explained by formation of denser fibrin clots.
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Highlights
• In patients with cerebral venous sinus thrombosis 
(CVST) elevated lipoprotein(a) is associated with unfa-
vorable fibrin clot features.
• Patients with lipoprotein(a) > 30 mg/dL have a 3.9-fold 
higher risk of recurrent CVST.
• It might be speculated that CVST patients with 
lipoprotein(a) > 30 mg/dl should be anticoagulated on 
the long-term basis.
Introduction
Cerebral venous sinus thrombosis (CVST) is a rare throm-
botic disease with its estimated annual incidence of 3–4 
cases per million [1]. However, recent studies suggested 
much higher incidence from 13.2–15.7 cases per million 
[2, 3]. The clinical presentation depends on the site and 
extension of the affected sinuses in CVST as well as on the 
presence of venous collaterals. It varies considerably from 
the most common severe headache to focal neurological 
deficits [4]. Several risk factors for CVST have been rec-
ognized including oral contraceptive use, pregnancy, infec-
tions, inflammatory diseases, and thrombophilia [1, 5]. The 
overall incidence of recurrent venous thromboembolism in 
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patients with CVST was about 2.03 per 100 person-years 
and it was highest in the first year after discontinuation of 
anticoagulant therapy [6].
In 2015 a novel risk factor for CVST unrelated to cancer 
and trauma was identified, the so-called prothrombotic fibrin 
clot phenotype [7]. It has been found that faster formation 
of denser plasma fibrin clots displaying reduced susceptibil-
ity to lysis characterizes patients with CVST, and impor-
tantly, denser clot structure may predispose to recurrence of 
CVST. Similar clot features have been reported in patients 
with cardiovascular disease, including ischemic stroke, and 
importantly, a predictive value of increased clot density and 
impaired lysability has been shown in patients with venous 
thromboembolism (VTE) [8–10]. One of several factors 
unfavorably affecting plasma clot properties is elevated 
lipoprotein(a) [Lp(a)] that consists of a low-density lipo-
protein (LDL) and apolipoprotein(a) [apo(a)] bound to an 
apolipoprotein B-100 by a disulfide linkage [11]. The apo(a) 
protein contains a varying number of kringle domains, 
which are homologous with kringle domains IV and V in the 
plasminogen particle [12, 13]. The levels of Lp(a) are highly 
heritable, exceeding 90% in European populations [14, 15]. 
The similar structure of apo(a) and plasminogen suggests 
that Lp(a) may inhibit fibrinolysis [16, 17]. However, on 
a molar basis, plasminogen is almost always in excess of 
apo(a), which calls into question its in vivo potency in inhib-
iting plasminogen activity [18].
Evidence linking increased Lp(a) with venous thrombosis 
is inconsistent [19–21]. Associations of elevated Lp(a) with 
CVST are unclear. To our knowledge, there have been case 
reports on the occurrence of CVST in patients with markedly 
increased Lp(a) levels [22–24] with one case of recurrence 
of CVST [23].
Elevated Lp(a) levels have been reported to be associated 
with decreased clot permeability and susceptibility to lysis 
in apparently healthy individuals, patients with advanced 
coronary artery disease and acute ischemic stroke [25–27] 
as well as those with residual vein obstruction [28]. Given 
associations of Lp(a) with prothrombotic clot phenotype and 
its presence in patients following CVST, we hypothesized 
that elevated Lp(a) can contribute to CVST and its recur-
rence in association with unfavorable fibrin clot features. 
Therefore, the aim of the current study is to investigate the 
links of Lp(a) with CVST in a cohort study.
Methods
Between January 2006 and May 2017, 80 consecutive adult 
patients with the first-ever CVST episode were recruited at 
the Center for Coagulation Disorders in Krakow, includ-
ing a group reported in 2015 [7]. We enrolled additional 30 
patients and collected data for long-term follow-up. CVST 
was objectively documented by computed tomography angi-
ography, magnetic resonance imaging or magnetic resonance 
angiography. Exclusion criteria were age above 60 years, 
current anticoagulation, recent trauma, other thromboem-
bolic events such as deep vein thrombosis, pulmonary embo-
lism and myocardial infarction in the past, severe inflamma-
tory diseases and known malignancy. Patients were eligible 
after at least 3 months of anticoagulant therapy and at least 
4 weeks since the last dose of an anticoagulant, mostly vita-
min K antagonists. Demographic data, location of thrombo-
sis and medical history focusing on potential risk factors for 
CVST were recorded.
Follow-up started after withdrawal of anticoagulant ther-
apy and was recorded every 6 months by visit to our center 
or by telephone contact. Documented recurrences of symp-
tomatic CVST by imaging studies were recorded. Follow-up 
was censored at the time of recurrence.
The bioethical committee approved the study and its par-
ticipants gave informed consent.
Laboratory investigations
Fasting blood sample were drawn in the morning. Full 
blood cell count, creatinine, glucose, international nor-
malized ratio (INR) and activated partial thromboplastin 
time (APTT) were assessed by standard laboratory assays. 
Fibrinogen was determined by the Clauss method. High-
sensitivity CRP was evaluated by nephelometry. Plasma 
D-dimer, plasminogen activator inhibitor-1 antigen (PAI-
1:Ag), tissue-type plasminogen activator antigen (tPA:Ag) 
were determined using commercially available immunoen-
zymatic assays. Lipoprotein(a) was measured by an immu-
noenzymatic assay (DRG Diagnostics, Marburg, Germany). 
Thrombophilia screening, including protein C, protein S, and 
antithrombin deficiencies, antiphospholipid antibodies, fac-
tor (F)V Leiden, and prothrombin 20210A polymorphisms 
were performed in all study participants as described previ-
ously [9, 29].
To evaluate fibrin clot properties, blood samples (vol/vol, 
9:1 of 3.2% trisodium citrate) were centrifuged at 2560 g 
for 20 min and the supernatant was aliquoted and stored 
at − 80 °C. All fibrin variables were assessed in duplicate. 
Interassay variability for all fibrin variables was < 8%.
Clot permeation
Briefly, to 120 µL citrated plasma 20 mmol/L calcium chlo-
ride and 1 U/mL human thrombin were added. After incu-
bation, the plasma clot was percolated with Tris buffer and 
its volume flowing through the gels were measured. A per-
meation coefficient  (Ks), was calculated from the equation: 
 Ks = Q × L × η/t × A × ∆p, where Q is the flow rate in time 
t; L is the length of a fibrin gel; η is the viscosity of liquid 
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(in poise); A is the cross-sectional area (in  cm2) and ∆p is 
differential pressure (in dyne/cm2). The lower  Ks, the more 
tightly packed a fibrin structure.
Turbidity measurements
Briefly, plasma citrated samples were mixed 2:1 with Tris 
buffer, which contained 0.6 U/mL human thrombin and 
50 mM calcium chloride. Absorbance was read at 405 nm. 
The lag phase of the turbidity curve, and the maximum 
absorbance of a gel (∆Abs) at the plateau phase were 
recorded.
Plasma clot lysis assays
To assess the efficiency of clot lysis two methods were used. 
Briefly, clot lysis time (CLT) was measured in the assay in 
which citrated plasma was mixed with 15 mmol/L calcium 
chloride, 0.6 pmol/L human tissue factor ,12 µmol/L phos-
pholipid vesicles and 60 ng/mL recombinant tPA (rt-PA).
The turbidity was measured at 405 nm at 37 °C. CLT was 
defined as the time from midpoint of the clear-to-maximum 
turbid transition to the midpoint of maximum-turbid-to-clear 
transition. In the second assay to measure fibrinolysis after 
clot formation and stabilization, fibrin clots, formed as for 
permeability evaluation, were perfused with a Tris buffer 
containing 0.2 µmol/L rt-PA D-dimer concentrations were 
measured every 20 min. The measurement was stopped 
when the gel collapsed under the pressure. Maximum rate of 
increase in D-dimer levels (D–Drate) and maximum D-dimer 
levels (D–Dmax) were analyzed.
Statistical analysis
Continuous variables were presented as means (standard 
deviation) or median (interquartile range), as appropriate. 
The Shapiro–Wilk test was used to test the normal distribu-
tion of variable. Categorical variables were reported as per-
centage. The Chi square test or Fisher exact test were used 
to compare the distribution of categorical variable. Analysis 
of variance for continuous variables was used to assess inter-
group differences. Analysis of covariance was used to com-
pare the mean difference in fibrin clots properties between 
groups after adjustment for fibrinogen. Correlations were 
assessed by the Pearson correlation coefficient. Multiple 
logistic regression analysis was performed to determine the 
effect of Lp(a) and fibrin clot properties on the rate of recur-
rences. Each variable was assessed by model with fibrino-
gen and sex and those < 0.05 were entered into multivariable 
analysis. The discrimination ability of a logistic model was 
used to report the area under the ROC curve with 95% CI. 
Statistical analyses were performed using SPSS 23.0 (SPSS 
Inc., Chicago, IL, USA). P-values < 0.05 were accepted as 
statistically significant.
Results
Eighty patients aged 39.36 ± 10.18 years following the first 
documented episode of CVST were studied (Table 1). Most 
patients were women (78.75%), including 25 (39.68%) 
on oral contraceptives and 14 (22.22%) diagnosed while 
pregnant. A positive family history of VTE was noted in 
19 subjects (23.75%). The CVST occurred during infection 
in 8 (10%) patients. Concomitant occurrence of VTE was 
observed in 9 (11.25%) patients. 12 (15%) patients were car-
riers of factor V Leiden, 5 (6.25%) patients had 2021A pro-
thrombin mutation, 5 (6.25%) had deficiency of antithrom-
bin, protein C or S, while antiphospholipid syndrome (APS) 
was observed in 5 (6.25%) patients.
A single sinus was affected in 43 (53.75%) patients. The 
most common site of CVST, which involved single sinus was 
the transverse sinus in 17 (21.25%) patients, followed by the 
sagittal sinus in 16 (20%) and the sigmoid sinus in 6 (7.5%) 
patients. One patient had venous sinus thrombosis isolated 
to the cavernous sinus. 37 (46.25%) patients had CVST in 
two or more sinuses.
Median Lp(a) in our cohort was 15.3 (9.8–27.7) mg/dL. 
The Lp(a) levels were positively associated with fibrinogen 
(r = 0.33, P = 0.003).No other correlations between Lp(a) 
levels and age, gender, number of sinuses affected, BMI, 
routine laboratory investigations, including D-dimer were 
observed. Moreover, there were no associations of Lp(a) lev-
els with tPA and PAI-1. Patients with CVST in other loca-
tions had significantly increased Lp(a) levels compared with 
the remainder (30.3 [18.7–33.3] versus 14.2 [9.5-25.05] mg/
dL, P = 0.016). In patients with the remaining sites affected 
by CVST compared with the rest no differences in Lp(a) 
levels were found.
As shown in Fig. 1, Lp(a) was strongly negatively corre-
lated with  Ks (r = − 0.58, P < 0.001, panel A) and positively 
associated with maximum absorbance of fibrin gels (r = 0.42, 
P < 0.001, panel B), indicating increased plasma clot density. 
Lag phase on turbidimetric curves was not related to Lp(a). 
Moreover, Lp(a) showed a positive correlation with D–Dmax 
(r = 0.29, P = 0.01, panel C), which indicates increased clot 
density at high Lp(a) levels. Lp(a) showed an inverse asso-
ciation with D–Drate (r = − 0.27, P = 0.017, panel D), but no 
association was observed between Lp(a) and CLT.
Follow‑up data
During a median follow-up of 53  months (interquar-
tile range 40–59), recurrence of CVST was observed in 
12 patients (15%) with an annual rate of 3.7% (95% CI 
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1.09–8.77%) person-year. The rate at first year was 1.25%. 
A median time since anticoagulation withdrawal to the 
second event was 26 months (19.8–34.3). Provoked recur-
rences were noted in 5 (42%) patients. Males were over-
represented in the group with recurrence of CVST with 
no other differences in basic characteristics and routine 
laboratory investigations including fibrinogen. There were 
also no differences in thrombophilic risk factors related to 
CVST recurrences (Table 1). Patients with recurrent CVST 
had 4.5% shorter APTT compared to the remainder, but 
still all values were within the reference range. Recur-
rence of CVST occurred predominantly in patients with 
multiple sinuses affected at the first event (n = 8, 66.67%). 
In 8 patients with recurrent CVST the involved sites dur-
ing the first episode were the sagittal and sigmoid sinuses 
(66.67%), followed by the transverse sinus (50%).
The levels of Lp(a) were 2 times higher in patients with 
recurrence of CVST compared to the remainder (Table 1; 
Fig. 2)
Table 1  Characteristics of patients with CVST with or without recurrence during follow-up
Values are given as mean ± standard deviation or median (interquartile range)
*Patients without recurrence vs patients with recurrence of CVST
a P values were adjusted for fibrinogen
Patients with CVST (n = 80) Without recurrence (n = 68) With recurrence (n = 12) P*
Age, years 39.36 ± 10.18 39.49 ± 10.16 38.67 ± 10.71 0.8
Female, n(%) 61 (76.25) 55 (88.8) 6 (50) 0.02
Body mass index, kg/m2 27.39 ± 4.33 27.24 ± 4.25 28.25 ± 4.85 0.46
Risk factors of CVST, n(%)
 Oral contraceptive 25 (31.25) 23 (33.82) 2 (16.67) 0.24
 Past pregnancy 14 (17.5) 11 (16.18) 3 (25) 0.46
 Cigarette smoking 18 (22.5) 16 (23.53) 2 (16.67) 0.6
 Family history of thrombosis 18 (22.5) 14 (20.6) 4 (33.33) 0.33
Thrombophilia
 Factor V Leiden 12 (15) 9 (13.24) 3 (25) 0.3
 Prothrombin 20210A mutation 5 (6.25) 4 (5.88) 1 (8.33) 0.75
 Deficiency of antithrombin, protein C or S 
deficiency
5 (6.25) 5 (7.35) 0 (0) 0.62
 Antiphospholipid syndrome 5 (6.25) 4 (5.88) 1 (8.33) 0.95
Laboratory investigations
 Creatinine, µmol/L 71 (60-78.25) 70.5 (60–78) 75 (62.5–82.5) 0.33
 Glucose, mmol/L 4.84 ± 0.51 4.82 ± 0.51 4.99 ± 0.54 0.28
 White blood cells, × 109/L 6.63 ± 1.7 6.72 ± 1.68 6.13 ± 1.79 0.27
 Platelets, × 109/L 215.5 (179.5–259) 209 (167.5–259) 227 (197.5-290.5) 0.16
 Hemoglobin, g/dL 13.85 ± 1.34 13.89 ± 1.38 13.65 ± 1.13 0.58
 INR 1.02 ± 0.09 1.01 ± 0.1 1.03 ± 0.09 0.52
 APTT, s 29.2 (28.1–31.2) 29.2 (28.5–31.3) 27.9 (26.6–29.5) 0.03
 Fibrinogen, g/L 2.9 (2.57–3.21) 2.87 (2.57–3.18) 3.08 (2.7–3.35) 0.23
 C-reactive protein, mg/L 1.85 (0.92–3.2) 1.92 (0.84–3.2) 1.32 (0.98–2.85) 0.54
 D-dimer, ng/mL 256(207–324) 252 (210–319) 263(199–346) 0.89
 Tissue plasminogen activator, ng/mL 9.56 ± 2.06 9.56 ± 2.18 9.53 ± 1.25 0.97
 Plasminogen activator inhibitor-1, ng/mL 24.82 ± 5.68 24.7 ± 5.88 25.46 ± 5.59 0.67
 Lipoprotein(a) (mg/dL)a 15.3 (9.8–27.7) 14.15 (8.85–25.25) 28.3 (18.9–35.6) 0.001
Fibrin clot  propertiesa
 Ks,  10−9 cm2 6.57 ± 0.95 6.7 ± 0.86 5.77 ± 1.1 0.001
 Lag phase, s 40 (38–43) 40.5 (38–43) 40 (37–43) 0.58
 ∆Abs (405 nm) 0.89 ± 0.06 0.85 ± 0.06 0.88 ± 0.06 0.4
 CLT, min 99.68 ± 17.23 99.1 ± 17.22 102.9 ± 17.66 0.67
 D–Dmax, mg/L 4.34 ± 0.51 4.28 ± 0.47 4.72 ± 0.55 0.008
 D–Drate, mg/L per minute 0.069 ± 0.004 0.069 ± 0.004 0.067 ± 0.005 0.23
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The risk of recurrent CVST was 3.9-fold higher among 
17 (21.25%) patients with Lp(a) > 30 mg/dL compared with 
the remainder (HR adjusted for fibrinogen = 3.9, 95% CI 
1.23–12.4; Fig. 3).
Recurrence of CVST was associated with 14% lower  Ks 
and 10% higher D–Dmax, measured at the time of antico-
agulation withdrawal. No other differences between fibrin 
variables were noted (Table 1).
Fig. 1  Correlations between Lp(a) and  Ks (panel A), ∆Abs (405 nm, panel B), D–Dmax (panel C), D–Drate (panel D)
Fig. 2  Lp(a) levels for patients with and without recurrence of CVST. 
Horizontal lines denote the medians for each group
Fig. 3  Kaplan–Meier curves of recurrent CVST during follow-up 
with regard to Lp(a) (log-rank P = 0.01)
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Multiple logistic regression model adjusted for fibrinogen 
and sex showed that CVST recurrence was independently 
associated with higher levels of Lp(a) (odds ratio 1.09, 95% 
confidence interval 1.02–1.16) (Table 2).
 
Discussion
To our knowledge it is the first study to demonstrate that 
elevated Lp(a) is often observed in patients following CVST 
and notably, this variable can predict recurrent CVST during 
a few years of follow-up. This study extends the previous 
findings in the role of Lp(a), suggesting its contribution to 
another thrombotic disorder. Importantly, we found that in 
patients following CVST, elevated Lp(a) levels are associ-
ated with decreased fibrin clot permeation, which is consist-
ent with observations reported in other patient populations 
at risk of thromboembolic events [25–28, 30, 31]. Moreo-
ver, a positive correlation between Lp(a) and D–Dmax was 
observed in our cohort and patients on long-term haemodial-
ysis, strengthening the association between increased plasma 
clot density and higher levels of Lp(a) [31]. Importantly, in 
the current study Lp(a) correlated inversely with D–Drate, 
indicating impaired fibrinolysis, which is in line with previ-
ous findings [28]. No such association was found between 
CLT and Lp(a). This study suggests that higher levels of 
Lp(a) may contribute to prothrombotic fibrin clot phenotype 
in patients with CVST. However, a novel finding is identi-
fication of Lp(a) as an independent risk factor for CVST 
recurrences, which suggests additional mechanisms linking 
Lp(a) with CVST beyond fibrin-related effects.
Impaired fibrinolysis in patients with higher levels of 
Lp(a) could be explained partly by inhibition of plasmi-
nogen binding to fibrin and the interference with conver-
sion of Glu-plasminogen to Lys-plasminogen and there-
fore reduction of the amount of plasmin in the tissue-type 
plasminogen activation [16, 17, 32]. Recently, Stachowicz 
et al. found in plasma fibrin clots from 4 patients with 
venous thromboembolism the presence of apo(a), which 
confirms that Lp(a) binds to clots and might affect clot 
structure and function including susceptibility to lysis 
[33]. The associations of Lp(a) with clot properties 
reported previously and the current work appear to con-
firm this hypothesis.
Regarding recurrences during follow-up, we confirmed 
previous observations made in a group of 50 patients indi-
cating that  Ks and D–Dmax are factors determining CVST 
[7]. Males were more likely to experience recurrence of 
CVST in the present study, which is consistent with find-
ings of Martinelli et al. [6]. The current study shows that 
impact of elevated Lp(a) on recurrent CVST is observed 
also after adjustment for fibrinogen and sex.
Our study has several limitations. Firstly, the size of 
the study group was limited particularly in the subgroup 
analysis. Secondly, each analyzed variable was assessed 
only once at a single time and thus analyses should be 
interpreted with caution. Moreover, the results of this 
study cannot be easily extrapolated to patients older than 
60 years and individuals with previous thromboembolic 
events. We did not analyze genetic polymorphisms of 
Lp(a) gene and its effects on association between Lp(a) 
levels and fibrin clot properties. However, our previous 
work showed that in apparently healthy individuals and 
patients following myocardial infarction the number of 
kringle IV repeats and pentanucleotide repeats were posi-
tively correlated with  Ks and negatively with clot lysis 
time,  t50% [30]. Thus, it can be assumed that elevated Lp(a) 
levels are associated with unfavorable clot properties.
In conclusion, we reported for the first time that 
increased Lp(a) characterizes subjects with higher risk of 
CVST recurrence after cessation of anticoagulation, which 
could be in part driven by prothrombotic fibrin clot phe-
notype expressed by denser clot structure and impaired 
fibrinolysis. A value of elevated Lp(a) as a risk factor of 
CVST remains to be assessed in other populations. The 
Table 2  Multiple logistic 
regression models adjusted for 
fibrinogen for patients with 
recurrence of CVST
*multiplied by 10
**multiplied by 100
Models with fibrinogen and sex Multivariable
Odds ratio (95%CI) P Odds ratio (95%CI) P
Lipoprotein(a) (mg/dL) 1.11 (1.03–1.17) 0.007 1.09 (1.02–1.16) 0.01
D–Dmax, mg/L 5.72 (1.12–29.29) 0.036 3.84 (0.87–16.93) 0.08
Ks,  10−9cm2 0.29 (0.11–0.76) 0.012 0.58 (0.22–1.54) 0.27
∆Abs (405 nm)* 1.49 (0.45–4.9) 0.52
CLT, min 1.01 (0.97–1.05) 0.75
Lag phase, s 1.01 (0.85–1.29) 0.68
D–Drate, mg/L per minute** 0.56 (0.13–2.42) 0.43
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present study has potential practical implications. It might 
be speculated that patients with Lp(a) > 30 mg/dl should 
be anticoagulated on the long-term basis given elevated 
risk of CVST recurrences. However, in view of bleeding 
risk, such approach should be tested in a larger study.
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